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Abstract
Introduction: Prolactinomas are the most common pituitary adenomas. 
Medical therapy with dopamine agonists (DAs) is the mainstay of treatment 
and rarely requires surgical manipulation. Patients may rarely present with 
cerebrospinal fluid (CSF) rhinorrhoea after starting therapy with DA in 
case of massive or invasive prolactinomas. Case Description: We present 
a case of a 29-year-old lady with invasive prolactinoma who presented 
with CSF rhinorrhoea after a month of starting bromocriptine therapy 
with the development of meningitis and warranting early surgical repair. 
Practical Implications: Patients with macroprolactinoma should be 
closely monitored initially after starting on DA to avoid life-threatening 
complications.
Key words: Cerebrospinal fluid, Dopamine agonists, meningitis, 
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Introduction
Prolactinoma is a benign growth of lactotrophs 
of the anterior pituitary gland causing excessive 
production of prolactin (PRL). The predominant 
biologically active form of PRL is a single-chain 
polypeptide of 198 amino acids and a molecular 
weight of 22 kDa.[1] Its secretion from the anterior 
pituitary gland is under the inhibitory effect of 
dopamine. Prolactinomas are often detected 
earlier in women secondary to PRL inhibitory effects 
on gonadotropins and subsequent menstrual 
abnormalities and galactorrhoea. On the contrary, 
the diagnosis is often delayed in men, and tumour 
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size is usually bigger when patients seek medical 
attention. Symptoms in men are mostly due to mass 
effects on surrounding structures such as optic 
chiasm causing visual disturbance and headache. 
Likewise, they may also present with erectile 
dysfunction.[2]
Despite being considered benign, many 
prolactinomas are invasive (30–45%),[3] with up 
to 15% being clinically aggressive.[4,5] Aggressive 
and invasive adenomas can invade the floor of the 
pituitary fossa extending into the sphenoid sinus. 
The pituitary gland lies outside the meningeal 
covering of the brain with cerebrospinal fluid (CSF) 
in arachnoid space. Erosion of sphenoidal sinus by 
invasive pituitary adenoma creates communication 
between arachnoid space and sphenoidal sinus, 
and CSF could potentially leak from these sites. 
This channel is blocked by an invading tumour, 
which serves as a plug, thus preventing CSF 
escape. Depending on the type of tumour and 
extent of invasion, some patients may experience 
CSF leakage from arachnoid space to sphenoid 
sinus that then finds its way to the nasal cavity 
through the sphenoid sinus opening in the nasal 
cavity. This unwanted, pathological and potentially 
life-threatening communication between the nasal 
cavity and intracranial cavity can be iatrogenic 
in patients with large invasive or malignant 
prolactinomas treated with pharmacological 
agents.[4,6]
Dopamine agonists (DAs) have proven to be 
excellent pharmacological agents in the treatment 
of prolactinomas. The response of the therapy is 
quick, and the response rates are good to excellent. 
Pituitary surgeries are seldom required, even in 
patients with the impending risk of visual loss due 
to tumour pressure on optic chiasm or optic tracts. 
The reduction in tumour size and regression of 
tumours from the sphenoid sinus can potentially 
leave a catastrophic communication between the 
intracranial cavity and sphenoid sinus in cases of 
large invasive prolactinomas.[6]
In this report, a clinical case of large invasive 
prolactinoma with CSF rhinorrhoea has been 
presented. The informed consent for publication of 
this case report was waived by the local Institutional 
Review Board (IRB# Ex-04-12-20-01).
Case Report
A 29-year-old lady presented to the endocrinology 
clinic with a history of galactorrhoea and 
amenorrhoea for the past 7 months. Furthermore, 
she reported the presence of headache and visual 
disturbances for 1 month. Physical examination 
revealed bilateral galactorrhoea with normal vital 
signs, no signs of hypo or hyperthyroidism and 
normal visual fields. Her magnetic resonance 
imaging (MRI) brain study showed a 4.5 cm × 3.8 cm 
× 2.8 cm sellar and suprasellar mass [Figure 1]. Her 
PRL level was raised with low follicular-stimulating 
hormone and luteinising hormone levels [Table 1]. 
Based on history, laboratory workup and MRI 
findings, it was diagnosed as a case of pituitary 
macroadenoma-PRL secreting. Her case was 
discussed in the multidisciplinary tumour meeting, 
and the board decided that the patient should be 
started on medical treatment with DA. She was 
Figure 1: T1 post-gadolinium sagittal magnetic resonance 
image is demonstrating large sellar and suprasellar 
enhancing mass which is eroding and expanding the sellar 
floor and extending to the sphenoid sinus (red arrow) 
inferiorly and cranially it is extending to the hypothalamic 
region (yellow arrow)
Journal Of Cancer & Allied Specialties 3
J Cancer Allied Spec 2021;7(1):4 Case Report
prescribed bromocriptine 7.5 mg 3 times a day 
and called for a follow-up in a month.
At 1-month follow-up, the patient reported a 2-day 
history of a clear, watery nasal discharge from her 
left nostril. This was not associated with flu-like 
symptoms, such as fever, watery eyes, blocked 
nose, post-nasal drip, fatigue or lethargy. The 
discharge increased in volume on bending forward. 
Diagnosis and management
The patient’s history and recent development 
of nasal discharge were suspected to be CSF 
rhinorrhoea. The diagnosis was confirmed on 
computerised tomography (CT) scan [Figure 2] of 
her brain. The images suggested erosion of the sella 
turcica, tuberculum sellae and right-sided roof of 
the posterior ethmoidal cells with the extension of 
the tumour into the sphenoid sinus. The patient was 
prescribed acetazolamide 500 mg 2 times a day until 
she could undergo the bony defect’s surgical repair. 
While the patient was waiting for her surgery, she 
presented with altered sensorium and neck rigidity. 
Her clinical and biochemical features confirmed 
the diagnosis of meningitis. She was managed 
along these lines, and she made a full recovery. 
Her MRI brain [Figure 3] at this stage confirmed 
stable pituitary mass involving seller, suprasellar 
and parasellar regions with an invasion of the 
sphenoid sinuses and mass effect on the third 
ventricle causing hydrocephalus. 
She underwent surgery to insert a lumbar drain 
for ventricular decompression followed by 
endoscopic trans-sphenoidal resection of the 
pituitary macroadenoma and repair the dural 
defect responsible for the CSF leak with fascia 
lata graft from the right thigh. Histopathology 
revealed benign pituitary adenoma and stained 









Prolactin (1.90–25 ng/ml) 188 ng/ml 14.3 ng/ml 2.61 ng/ml 10 ng/ml
Thyroid-stimulating hormone (0.55–4.78 uIU/ml) 0.934 uIU/ml - 0.714 uIU/ml 0.67 uIU/ml
Free T4 (0.89–1.76 ng/dl) 1.17 ng/dl 1 ng/dl 1.76 ng/dl 0.77 ng/dl
Cortisol 15.66 ug/dl 12.3ug/dl 11.09 ug/dl 0.53 ug/dl
Luteinising hormone 0.168 mIU/ml - - -
Follicle-stimulating hormone 0.423 mIU/ml - - -
Insulin-like growth factor-1 (88–537 ng/ml) 210 ng/ml - - -
Serum sodium (136–145 mmol/L) 142 mmol/L 140 mmol/L 150 mmol/L 143 mmol/L
Figure  2:  Coronal unenhanced computerised 
tomography image in the bone window at the level of 
the anterior clinoid process reveals a bony defect in the 
sellar floor/superior wall of the sphenoid sinus (arrow) 
through which sellar tumour is making its way to the 
sphenoid sinus
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she developed diabetes insipidus and secondary 
hypothyroidism and was started on desmopressin 
and thyroxine. 
On follow-up visits, the patient had improvement 
in her symptoms with no recurrence of CSF 
rhinorrhoea. She continued with her treatment of 
bromocriptine 7.5 mg 3 times daily. After a few 
months, her PRL levels dropped to 10 ng/ml, and 
an MRI brain revealed a residual stable pituitary 
lesion [Figure 4].
Discussion
CSF rhinorrhoea is a relatively uncommon 
complication of prolactinoma treatment. In one 
series of 114 macroprolactinoma patients, the 
incidence of DA-induced CSF rhinorrhoea was 
6.1%.[7] It was reported that CSF rhinorrhoea was 
more common in men than women, and there 
was no age predominance. Similar findings were 
reported by de Lacy et al.[8] The investigators found 
the occurrence of CSF rhinorrhoea in 38  men, 
18 women and 4 unspecified gender cases. Skull 
base defects were reported in 43 (out of 60) cases. 
The time from DA therapy to the occurrence of 
rhinorrhoea was approximately ranging from 
1 week to 4 years, with a median of 6 weeks.[8] This 
is similar to the findings of the present case report. 
This patient presented with rhinorrhoea after nearly 
1 month of starting bromocriptine therapy. It has 
been proposed that volume reduction following DA 
therapy leads to exposure of the previously created 
pathological opening in the skull base, which was 
plugged by the tumour itself (until shrinkage of the 
tumour decompensated it). Similarly, in this case, 
the patient had evidence of skull erosion and sinus 
invasion on initial imaging. 
There is no definite consensus in literature at a 
molecular level to suggest the cause of tumour 
aggressiveness. Some have suggested that the 
upregulation of protease-activated receptor 1 is 
a key factor in cellular invasiveness and tumour 
Figure  4: Post-trans-sphenoidal resection of the 
sellar/suprasellar tumour. Follow-up sagittal T1 post-
gadolinium magnetic resonance image in midline shows 
post-surgical changes in the sphenoid sinus with residual 
mucosal thickening, surgical defect in the sellar floor and 
residual enhancing tissue in the sellar/suprasellar cistern
Figure  3: Coronal T2-weighted magnetic resonance 
image of the brain at the level of the sphenoid sinus 
with pituitary protocol shows T2 hyperintense fluid in 
the sphenoid sinus with similar intensity as cerebrospinal 
fluid (CSF) (arrow) worrisome of CSF leak through defect 
in sellar floor
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progression.[9] However, others have hypothesised 
that the loss of epithelial cadherin expression on 
prolactinomas is a cause of invasion and erosion 
of the sphenoidal bone.[10]
Patients with CSF rhinorrhoea can present to the 
clinic with a watery discharge from the nose in the 
absence of common cold or flu-like symptoms. This 
can be the initial presenting symptom in patients 
with a pituitary tumour.[11] Diagnosis can be delayed 
in such patients following the misdiagnosis of cold 
or flu. However, in some patients, the discharge is 
blood stained, which results in patients seeking 
immediate medical attention and subsequent 
investigations sooner. This communication between 
the nasal cavity and the intracranial cavity can lead 
to catastrophic consequences in some patients, 
such as meningitis, pneumocephalus or intracranial 
abscesses.[12]
Although CSF is transparent, thin in consistency, 
watery and sweet compared to salty, thick and 
sticky nasal discharge, it may be challenging to 
differentiate between CSF and nasal discharge 
on clinical findings alone if the two are mixed. 
The laboratory investigations for this purpose 
are relatively reliable and straightforward. Beta-
2-transferrin protein (tau protein) is unique to 
CSF and is produced by the loss of sialic acid due 
to the presence of neuraminidase in the central 
nervous system. Detection of beta-2-transferrin 
protein has shown to be highly sensitive and 
specific. Similarly, glucose detection has been 
suggested to detect the difference between 
persistent rhinorrhoea and otorrhoea. However, 
this test has shown to be unreliable. Alternatively, 
imaging investigations such as nuclear medicine 
CSF cisternography, CT cisternography or CT 
of the skull base can assist in diagnosing if 
laboratory testing is not available.[13]
Recommended initial treatment for the management 
of DA-induced CSF rhinorrhoea is surgical repair, 
and it should be offered as soon as possible.[14] 
The preferred approach is endoscopic endonasal 
surgical repair. The communication between the 
nasal cavity and the intracranial cavity must be 
closed. It is recommended to discontinue DA while 
waiting for surgery to let the tumour regrow and 
fill the gap. However, this is a temporary measure 
because DAs have to be used to treat prolactinoma. 
On the contrary, this may be the treatment of choice 
in patients not fit for surgical intervention. The dose 
of DA may need to be carefully titrated and then 
monitored with imaging to prevent modification in 
the size of the tumour. 
Debulking of adenoma is often considered 
before reconstruction of skull defect in some 
cases. However, a complete removal is usually 
not advisable, with tumours usually invading 
surrounding bones and dura mater that will require 
a more extensive surgical procedure. Debulking of 
the pituitary tumour will also provide space for the 
insertion of the graft, which is used for the repair 
of the bony defect. Following tumour debulking, 
repairing the skull base can be done using dural 
substitutes or fibrin glue for smaller leaks and 
autologous fat or fascia for larger leaks.[15] This 
patient underwent tumour debulking with the 
dural defect restoration using a fascia graft from 
the thigh. 
This case highlights the importance of follow-up 
after initiation of DAs in patients with prolactinomas. 
Even though DAs have simplified the treatment of 
prolactinomas, close surveillance of the patients 
is still necessary. Patients that develop CSF 
rhinorrhoea should undergo urgent definitive 
treatment to avoid life-threatening complications 
such as meningitis.
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